Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Large clinical trials for osteoporosis].

Pierre-Jean Meunier1

  • 1Service de Rhumatologie, Hôpital Edouard Herriot, Lyon, France.

Therapie
|December 20, 2003
PubMed
Summary

Effective osteoporosis treatments, including bisphosphonates and strontium ranelate, significantly reduce fracture risk in postmenopausal women. Early diagnosis and intervention remain crucial for preventing initial fractures.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimated number of women likely to benefit from bone mineral density measurement in France.

Joint bone spine·2004
See all related articles

Area of Science:

  • Orthopedics
  • Pharmacology
  • Gerontology

Context:

  • Osteoporosis poses significant public health challenges due to population aging and fracture-related costs.
  • Guidelines for evaluating osteoporosis treatments have advanced over the past decade.
  • Combination therapy with calcium and vitamin D shows benefits, particularly in older individuals.

Purpose:

  • To review current therapeutic strategies for postmenopausal osteoporosis.
  • To evaluate the efficacy of various pharmacological agents in preventing and treating osteoporosis and fractures.

Summary:

  • Alendronate and risedronate demonstrate significant reductions in vertebral fracture risk and increases in bone mineral density (BMD).
  • Calcitonin and raloxifene also show efficacy in reducing vertebral fracture risk, though methodological criticisms exist for calcitonin.
  • Parathyroid hormone (PTH) and strontium ranelate offer novel mechanisms, with PTH reducing fracture risk by 65% and strontium ranelate showing a 41% decrease in vertebral fractures.

Impact:

  • Established therapeutic strategies improve postmenopausal osteoporosis management.
  • Despite advances, osteoporosis remains underdiagnosed and undertreated.
  • Prioritizing the prevention of the first fracture is essential.

Related Experiment Videos